KarMMA-3 Study: Idecabtagene Vicleucel in R/R MM

During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Taiga Nishihori, MD, discussed the current outpatient administration model of cilta-cel among patients with relapsed/refractory multiple myeloma.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Significant progress has been made since the approval of the first CAR T-cell therapy, but there is still tremendous room for improvement.

A cohort study of the KarMMa-2 trial discovered durable responses in patients with high-risk multiple myeloma treated with ide-cel.